BRPI0720991A8 - Preparação da romidepsina - Google Patents

Preparação da romidepsina

Info

Publication number
BRPI0720991A8
BRPI0720991A8 BRPI0720991A BRPI0720991A BRPI0720991A8 BR PI0720991 A8 BRPI0720991 A8 BR PI0720991A8 BR PI0720991 A BRPI0720991 A BR PI0720991A BR PI0720991 A BRPI0720991 A BR PI0720991A BR PI0720991 A8 BRPI0720991 A8 BR PI0720991A8
Authority
BR
Brazil
Prior art keywords
romidepsin
preparation
adducts
oligomerized
dimerized
Prior art date
Application number
BRPI0720991A
Other languages
English (en)
Inventor
L Verdine Gregory
H Vrolijk Nicholas
Bertel Stephan
Original Assignee
Gloucester Pharmaceuticals Inc
Celgene Corp
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gloucester Pharmaceuticals Inc, Celgene Corp, Sandoz Ag filed Critical Gloucester Pharmaceuticals Inc
Publication of BRPI0720991A2 publication Critical patent/BRPI0720991A2/pt
Publication of BRPI0720991A8 publication Critical patent/BRPI0720991A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PREPARAÇÃO DA ROMIDEPSINA. A presente invenção proporciona um processo aperfeiçoado para a preparação de romidepsina. O processo envolve a produção, purificação ou a armazenagem da romidepsina sob condições que impeçam a formação de adutos indesejáveis. A purificação de romidepsina em pH aparente mais baixo do que aproximadamente 6,0 (por exemplo, entre um pH aparente do 4,0 e 6,0) foi descoberta como impedindo a redução da ligação de dissulfeto da romidepsina e a formação subsequente de adutos dimerizados, oligomerizados, ou polimerizados. A invenção também proporciona composições farmacêuticas de romidepsina monomérica isenta de adutos dimerizados, oligomerizados, ou polimerizados.
BRPI0720991A 2006-12-29 2007-12-28 Preparação da romidepsina BRPI0720991A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88270406P 2006-12-29 2006-12-29
US88269806P 2006-12-29 2006-12-29
US60/882,704 2006-12-29
US60/882,698 2006-12-29
PCT/US2007/089067 WO2008083288A2 (en) 2006-12-29 2007-12-28 Purifiction of romidepsin

Publications (2)

Publication Number Publication Date
BRPI0720991A2 BRPI0720991A2 (pt) 2014-03-18
BRPI0720991A8 true BRPI0720991A8 (pt) 2016-03-15

Family

ID=39493420

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720991A BRPI0720991A8 (pt) 2006-12-29 2007-12-28 Preparação da romidepsina

Country Status (10)

Country Link
US (2) US8691534B2 (pt)
EP (1) EP2102230A2 (pt)
JP (1) JP2010514801A (pt)
CN (2) CN101801994A (pt)
AU (1) AU2007342028B2 (pt)
BR (1) BRPI0720991A8 (pt)
CA (1) CA2674309A1 (pt)
IL (1) IL199547A (pt)
MX (1) MX2009006969A (pt)
WO (1) WO2008083288A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2450049A1 (en) * 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
SG10201505475XA (en) * 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
AU2015202335B2 (en) * 2010-07-12 2017-02-02 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103173390B (zh) * 2013-03-16 2014-09-10 浙江海正药业股份有限公司 一种紫色杆菌菌株及其应用
CN104072589B (zh) * 2013-03-29 2017-09-22 浙江海正药业股份有限公司 抗肿瘤三硫化合物及其制备方法与应用
CN104447950A (zh) * 2013-09-18 2015-03-25 上海医药工业研究院 一种罗米地辛的分离纯化方法
CN104450837B (zh) * 2013-09-18 2019-01-01 上海医药工业研究院 一种用于生产罗米地辛的方法及发酵培养基
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN104262456B (zh) * 2014-09-11 2018-01-09 浙江海正药业股份有限公司 一种罗米地辛的新晶型及其制备方法和用途
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法
WO2020139453A2 (en) * 2018-12-24 2020-07-02 Marrone Bio Innovations, Inc. A method for increasing romidepsin production from fermentation broth
CN113549131B (zh) * 2021-08-05 2023-01-17 台州科技职业学院 一种合成罗米地辛二聚合物romipeptide A的制备方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
GB9001318D0 (en) * 1990-01-19 1990-03-21 Fujisawa Pharmaceutical Co Wb968 substances and preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
NZ503061A (en) 1997-09-02 2001-08-31 Japan Energy Corp Cyclic tetrapeptide derivatives and use as anti-cancer agents
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EA200601252A1 (ru) 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
EP1779859B1 (en) 1999-12-08 2010-06-09 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants in preventing or treating rejection following transplantation and for induction of apoptosis of activated CD4 or CD8 T-cells
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
US7396665B2 (en) * 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
CA2434269A1 (en) 2001-01-10 2002-07-18 The Government Of The United States Of America Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
HU229521B1 (hu) 2001-08-21 2014-01-28 Astellas Pharma Inc A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
US20040259772A1 (en) 2001-08-24 2004-12-23 Antonio Fojo Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
AU2002351898A1 (en) 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US20030134423A1 (en) 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
JP2005525345A (ja) 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
CN1646558B (zh) 2002-02-20 2010-05-12 国立大学法人九州工业大学 组蛋白脱乙酰酶抑制剂
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US20040077591A1 (en) 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
MXPA04009761A (es) 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040002447A1 (en) 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
WO2004009771A2 (en) 2002-07-24 2004-01-29 Advanced Stent Technologies, Inc. Stents capable of controllably releasing histone deacetylase inhibitors
US20050272647A1 (en) 2002-08-20 2005-12-08 Noboru Yamaji Arthrodial cartilage extracellular matrix degradation inhibitor
US7098186B2 (en) 2002-08-30 2006-08-29 Astellas Pharma Inc Depsipeptide compound
JP2006501267A (ja) 2002-09-13 2006-01-12 バージニア コモンウェルス ユニバーシティー 白血病の処置のためのａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよびｂ）ヒストンデアセチラーゼインヒビターの組合せ剤
SE0300098D0 (sv) 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US20080233562A1 (en) 2003-02-19 2008-09-25 Astellas Pharma Inc. Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor
WO2004096289A1 (ja) 2003-04-25 2004-11-11 Fujisawa Pharmaceutical Co 遺伝子導入効率増強剤
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
DK2238982T3 (da) 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
KR100924737B1 (ko) 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
JP2007505914A (ja) 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
PL1670514T3 (pl) 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
EP1689446B1 (de) 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
WO2005058298A2 (en) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
ATE437370T1 (de) 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
ES2308065T3 (es) 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
US20050261174A1 (en) 2004-05-20 2005-11-24 Paul Lewer Insecticidal activity of a cyclic peptide
WO2005117930A2 (en) 2004-06-04 2005-12-15 Sloan-Kettering Institute For Cancer Research Use of thioredoxin measurements for diagnostics and treatments
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
AU2005281704A1 (en) 2004-09-06 2006-03-16 Nycomed Gmbh Novel pyrazolopyrimidines
EP1812036A2 (en) 2004-11-17 2007-08-01 The University Of Chicago Histone deacetylase inhibitors and methods of use
WO2006060382A2 (en) 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006060429A2 (en) 2004-12-03 2006-06-08 Novartis Ag Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20060229237A1 (en) 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
JPWO2007020871A1 (ja) 2005-08-12 2009-02-26 アステラス製薬株式会社 デプシペプチド含有注射液
US7439695B2 (en) * 2005-08-19 2008-10-21 Komatsu America Corp. Mechanical braking system for use on a vehicle having an electric propulsion system and automatic retard speed regulation
US7943568B2 (en) 2005-09-30 2011-05-17 The Ohio State University Research Foundation Antitumor agents
JP2009515524A (ja) 2005-11-10 2009-04-16 アメリカ合衆国 Ａｂｃｂ１多型バリアントスクリーニング、診断及び処置のための物質及び方法
EP1965824A4 (en) 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
GB0524316D0 (en) 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
CA2632903C (en) 2005-12-02 2015-11-24 Vianova Labs, Inc. Treatment of cancer and other diseases
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
CN101516375B (zh) 2006-09-15 2012-10-03 詹森药业有限公司 类别-i具体组织蛋白脱乙酰基酶抑制剂与蛋白酶体抑制剂的组合
CA2670223A1 (en) 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
EP2450049A1 (en) 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
MX2009007777A (es) 2007-01-23 2009-12-16 Gloucester Pharmaceuticals Inc Terapia de combinacion que comprende romidepsina y bortezomib.
WO2008127659A2 (en) 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
WO2009067453A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US20110053991A1 (en) 2007-11-19 2011-03-03 Gore Lia Treatment of Histone Deacetylase Mediated Disorders
WO2009108755A2 (en) 2008-02-27 2009-09-03 Wyeth Pharmaceutical combinations for the treatment of cancer
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
JP2011519868A (ja) 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
WO2009137649A2 (en) 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
JP2011529904A (ja) 2008-07-30 2011-12-15 グルオウセステル プハルマセウトイカルス， インコーポレーテッド 加速された療法

Also Published As

Publication number Publication date
US20090186382A1 (en) 2009-07-23
US8691534B2 (en) 2014-04-08
CA2674309A1 (en) 2008-07-10
CN107090482A (zh) 2017-08-25
MX2009006969A (es) 2010-04-07
WO2008083288A3 (en) 2008-10-02
EP2102230A2 (en) 2009-09-23
US20090209616A1 (en) 2009-08-20
BRPI0720991A2 (pt) 2014-03-18
JP2010514801A (ja) 2010-05-06
IL199547A (en) 2017-09-28
AU2007342028A1 (en) 2008-07-10
AU2007342028B2 (en) 2013-06-13
WO2008083288A2 (en) 2008-07-10
CN101801994A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
BRPI0720991A8 (pt) Preparação da romidepsina
EP2124990A4 (en) TUMOR TREATMENT BASED ON ROMIDEPSIN
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
MX344973B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina.
TW200612892A (en) Novel compounds
BR112014015909A8 (pt) composição
BRPI0812609A2 (pt) método para separar pelo menos um componente de uma composição que compreenda pelo menos dois derivados de óleos de sementes
BRPI0519496A2 (pt) processo para preparar um composto ou uma composiÇço, e, composiÇço
ECSP088854A (es) Moduladores bencimidazolicos de vr1
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
CY1110943T1 (el) Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης
PY09010618A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112019002417A2 (pt) cristalização de glicosídeos de esteviol
TW200745003A (en) Novel compounds
AR050717A1 (es) Composiciones farmaceuticas
BRPI0508610A (pt) derivados de aminoácidos
BRPI0418474A (pt) solução aquosa parenteral estável
BR112013031146A2 (pt) liberação direcionada de compostos retinóides para as glândulas sebáceas
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
BRPI0408848A8 (pt) Composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
BR112015009453A2 (pt) composição farmacêutica estável de peg-interferona alfa-2b

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SANDOZ GMBH (AT) , CELGENE CORPORATION (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.